Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients
Teplizumab administration under compassionate use proved feasible and safe in a real-life academic context, consistent with pivotal trial data. The experience underscores the importance of a structured multidisciplinary approach, integrating endocrinologists, anaesthesiologists, nurses and psychologists to optimise adherence, safety and patient engagement during early disease-modifying immunotherapy in presymptomatic T1D.
Authors
- Giorgio Arnaldi (ORCID: https://orcid.org/0000-0002-6204-3423)
- Enrica Vigneri
- Felicia Pantò
- Laura Tomasello (ORCID: https://orcid.org/0000-0002-2304-6007)
- Giuseppe Piombo
- V. Guarnotta
- M. I. Mineo
Institutions
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1111/dom.70626
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00